Wellumio finalized an oversubscribed $9.75 million pre-Series A round to commercialize its portable Axana brain imaging device and expand clinical evaluation sites.
- Amount
- $9.8M
- Stage
- Pre-Seed
- Announced
- 24 July 2026
- Lead
- Nuance Connected Capital
- Other investors
- Bioshore Ventures, Jumpspace Ventures, Icehouse Ventures, NZGCP Aspire Seed Fund, Pacific Channel, Booster, Cure Kids Ventures, Enterprise Angels, Flying Kiwi, NZ Active Investor Plus program, Snowball Effect
- Use of funds
- Commercialize the Axana portable brain imaging device, expanding clinical evaluation sites across Australia, the US and New Zealand.
- Checked
- Amount and date matched across 2 press sources